Halozyme Therapeutics HALO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Bulk rHuPH20 sales | $73.5M+172% | $50.24M+155% | $32.49M+3.2% | $23.27M-5.5% | $27.03M+157% | |
| Device licensing and development revenue | $5.6M+64.4% | $5.38M+66.8% | $4M+18.8% | $4.07M+98.6% | $3.41M+26.1% | |
| Device partnered product sales | $15.05M+2.6% | $12.86M+4.0% | $9.5M-37.7% | $11.79M+16.6% | $14.68M+14.5% | |
| Proprietary product sales | $41.87M+15.2% | $59.57M+25.9% | $52.24M+30.9% | $46.45M+5.2% | $36.34M+3.1% | |
| Royalties | $240.68M+43.1% | $257.97M+51.4% | $236.04M+52.2% | $205.64M+64.6% | $168.19M+39.5% | |
| Sales-based milestones | $0-100% | $25M-16.7% | $20M— | $10M— | $15M— | |
| Upfront license and target nomination fees | $0-100% | $18.25M— | $0-100% | $0— | $220K— | |
| Accounts receivable, net and contract assets by Product | ||||||
| Device partnered product sales | $105.83M+106% | $69.83M+85.7% | $39.6M+7.3% | $31.15M+6.3% | $51.47M+90.3% | |
| Royalties | $298.12M+62.4% | $259.3M+57.8% | $233.03M+55.2% | $203.07M+58.6% | $183.58M+59.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Halozyme Therapeutics break its business down?
- Halozyme Therapeutics (HALO) reports revenue from contract with customer, excluding assessed tax by product across 7 parts — Bulk rHuPH20 sales, Device licensing and development revenue, Device partnered product sales, Proprietary product sales and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Halozyme Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Halozyme Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
